Vaccinex annual depreciation and amortization
2017
2018
2019
2020
2021
2022
2023
2024
Vaccinex Depreciation & Amortization Growth & History (VCNX)
Vaccinex's depreciation and amortization was $94,000 for fiscal 2024.
View full Vaccinex company overviewVaccinex annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $94,000 | −$25,000 | −21.01% |
| 2023 | 2023-12-31 | $119,000 | −$88,000 | −42.51% |
| 2022 | 2022-12-31 | $207,000 | $38,000 | +22.49% |
| 2021 | 2021-12-31 | $169,000 | −$138,000 | −44.95% |
| 2020 | 2020-12-31 | $307,000 | $58,000 | +23.29% |
| 2019 | 2019-12-31 | $249,000 | $26,000 | +11.66% |
| 2018 | 2018-12-31 | $223,000 | $17,000 | +8.25% |
| 2017 | 2017-12-31 | $206,000 | — | — |
Vaccinex quarterly depreciation and amortization
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | $17,000 | — | — |
| Q3 2024 | 2024-09-30 | $24,000 | −$7,000 | −22.58% |
| Q2 2024 | 2024-06-30 | $25,000 | −$5,000 | −16.67% |
| Q1 2024 | 2024-03-31 | $27,000 | −$4,000 | −12.90% |
| Q3 2023 | 2023-09-30 | $31,000 | −$36,000 | −53.73% |
| Q2 2023 | 2023-06-30 | $30,000 | −$24,000 | −44.44% |
| Q1 2023 | 2023-03-31 | $31,000 | −$10,000 | −24.39% |
| Q3 2022 | 2022-09-30 | $67,000 | $30,000 | +81.08% |
| Q2 2022 | 2022-06-30 | $54,000 | $19,000 | +54.29% |
| Q1 2022 | 2022-03-31 | $41,000 | −$14,000 | −25.45% |
| Q3 2021 | 2021-09-30 | $37,000 | −$37,000 | −50.00% |
| Q2 2021 | 2021-06-30 | $35,000 | −$52,000 | −59.77% |
| Q1 2021 | 2021-03-31 | $55,000 | −$20,000 | −26.67% |
| Q3 2020 | 2020-09-30 | $74,000 | $10,000 | +15.63% |
| Q2 2020 | 2020-06-30 | $87,000 | $30,000 | +52.63% |
| Q1 2020 | 2020-03-31 | $75,000 | $15,000 | +25.00% |
| Q3 2019 | 2019-09-30 | $64,000 | $10,000 | +18.52% |
| Q2 2019 | 2019-06-30 | $57,000 | −$55.9M | −99.90% |
| Q1 2019 | 2019-03-31 | $60,000 | $4,000 | +7.14% |
| Q3 2018 | 2018-09-30 | $54,000 | $0 | 0.00% |
| Q2 2018 | 2018-06-30 | $56.0M | $6.0M | +12.00% |
| Q1 2018 | 2018-03-31 | $56,000 | — | — |
| Q3 2017 | 2017-09-30 | $54,000 | — | — |
| Q2 2017 | 2017-06-30 | $50.0M | — | — |
Vaccinex depreciation and amortization trends
Over the last five fiscal years, Vaccinex's depreciation and amortization decreased from $249,000 to $94,000, a change of −$155,000. The latest reported quarter, Q4 2024, shows $17,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vaccinex source filings ↗